Patent ID: 8906412

Claim:
A method of treating ethanol withdrawal syndrome, alcohol addiction, or cocaine addiction in a patient, comprising administering to the patient in need of such treatment one or more sustained release oral tablets comprising: (a) 40 wt % to 65 wt % of 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid; (b) 1 wt % to 30 wt % of glyceryl behenate; and (c) 30 wt % to 50 wt % of dibasic calcium phosphate; wherein wt % is based on the total dry weight of the dosage form, which one or more tablets: when administered to one or more fasted human patients at a dose of 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid ranging from 1100 mg to 1300 mg provides a gabapentin plasma concentration profile characterized by a C max ranging from 3 μg/mL to 6 μg/mL, a T max ranging from 4 hours to 7 hours, and an AUC ranging from 30 μg·hr/mL to 70 μg·hr/mL; or when administered to one or more fed human patients at a dose of 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid ranging from 1100 mg to 1300 mg provides a gabapentin plasma concentration profile characterized by a C max ranging from 5 μg/mL to 8 μg/mL, a T max ranging from 6 hours to 11 hours, and an AUC ranging from 60 μg·hr/mL to 110 μg·hr/mL.